A Randomized, Double-blind, Placebo-controlled Phase I Clinical Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of SSS39 Injection by Single Intravenous Infusion in Healthy Chinese Subjects
Latest Information Update: 23 Jul 2025
At a glance
- Drugs Sirolimus (Primary)
- Indications Autoimmune disorders
- Focus Adverse reactions
- Sponsors Shenyang Sunshine Pharmaceutical
Most Recent Events
- 23 Jul 2025 New trial record